Pivotal phase III trial of ALZ 801 in patients with Alzheimer's disease positive for e4 allele of the apolipoprotein E
Phase of Trial: Phase III
Latest Information Update: 23 Jul 2018
At a glance
- Drugs ALZ 801 (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors Alzheon
- 23 Jul 2018 Data from responder analyses of this trial presented in an Alzheon Media Release.
- 23 Jul 2018 According to an Alzheon media release, data from patient responder analyses of this trial will be presented at 2018 Alzheimers Association International Conference.
- 02 Nov 2017 According to an Alzheon media release, data will be presented at the 10th Annual Clinical Trials on Alzheimers Disease (CTAD) congress which will be held in 1-4 Nov 2017.